ERA 2024 Highlights Podcast

This episode podcasts some of the events at the 61st European Renal Association (ERA) held 23-26 May, 2024 in Stockholm, Sweden. We start off by covering the double-blind, international FLOW (Evaluate Renal Function With Semaglutide Once Weekly) trial which was conducted to take on the issue with kidney measures in patients with CKD as a primary outcome.

The FLOW study, conducted in 28 countries, involved 3533 patients recruited between June 2019 and May 2021 who had CKD and type 2 diabetes. Patients were randomized to treatment with semaglutide 1.0 mg once weekly (n = 1767) or placebo (n = 1766), both in addition to standard care. It was stopped early due to a clear positive effect in the intervention arm. Listen to the podcast or read the article to learn more.

Did you know that about 11% of the world’s population has genetic kidney disease? That is 875 million people! While we were in Stockholm at the ERA24 last weekend we also had an opportunity to talk with Prof. John Sayer (University of Newcastle, UK) together with Prof. Roman-Ulrich Müller (University Clinic Cologne, Germany). We talk about how one-third of all renal failure is attributable to faulty genes, such as the deletion of NPHP1, and we also talk about the ethical considerations of sequencing all babies at birth.

Enjoy listening!



LinkedIn profile Prof. John Sayer

LinkedIn profile Prof. Roman-Ulrich Müller

Further reading

1. Meet the Experts: Navigating Kidneys and Genes


2. FLOW: Semaglutide improves kidney and cardiovascular outcomes in participants with type 2 diabetes and chronic kidney disease

Posted on 3 June 202427 June 2024